Pinto, A
Methods A comprehensive search was conducted across PubMed, Scopus, and Embase up to July 2024
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Apr 24, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 4,607 views Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity
From collagen formation to hydration balance, pigmentation support to elasticity, amino acids play a fundamental role in skin health
